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Objective: We investigated the relationship between the molecular weight (MW) distribution of hya-
luronan (HA) in synovial ﬂuid (SF) and risk of knee osteoarthritis (OA) progression.
Methods: HA MW was analyzed for 65 baseline knee SFs. At 3-year follow-up, knees were scored for
change in joint space narrowing (JSN), osteophyte (OST) progression, or occurrence of total knee
arthroplasty (TKA). HA MW distribution was analyzed using agarose gel electrophoresis (AGE), and its
relationship to OA progression was evaluated using logistic regression. The association between HA MW
and self-reported baseline knee pain was analyzed using Pearson's correlation coefﬁcients.
Results: Knee OA was categorized as non-progressing (OST/JSN, 26 knees, 40%), or progressing based
on OST (OSTþ/JSN, 24 knees, 37%), OST and JSN (OSTþ/JSNþ, 7 knees, 11%) or total knee arthroplasty
(TKA, 8 knees, 12%). The MW distribution of HA in baseline SFs was signiﬁcantly associated with the odds
of OA progression, particularly for index knees. After adjusting for age, gender, BMI, baseline X-ray grade
and pain, each increase of one percentage point in %HA below 1 million signiﬁcantly increased the odds
of JSN (odds ratios (OR) ¼ 1.45, 95% CI 1.02e2.07), TKA or JSN (OR ¼ 1.24, 95%CI 1.01e1.53) and the odds
of any progression (OR ¼ 1.16, 95% CI 1.01e1.32). HA MW distribution signiﬁcantly correlated with pain.
Conclusion: These data suggest that the odds of knee OA progression increases as HA MW distribution
shifts lower and highlight the value of reporting MW distribution rather than just average MW values for
HA.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Hyaluronan (commonly referred to as hyaluronic acid or HA) is
the polysaccharide responsible for the viscous and elastic proper-
ties of synovial ﬂuid (SF)1,2. Since the mid-twentieth century, a
reduction in the viscosity of SF has been associated with synovial
joint pathologies. Ropes et al. suggested that the reduction in the
viscosity of SF resulted from reduced polymerization of HA, and
was useful for the differential diagnosis of joint disease3. Shortly: P.A. Band, NYU School of
and@gmail.com (P.A. Band),
ki), vliublin@fas.harvard.edu
ternational. Published by Elsevier Lthereafter, the severity of inﬂammatory joint disease was reported
to be associatedwith a decrease in the concentration andmolecular
weight (MW) of HA in SF4. Sundblad demonstrated that degener-
ative joint disease (arthrosis deformans), commonly referred to as
osteoarthritis (OA), was likewise associated with a decrease in the
average MW of HA in SF based on intrinsic viscosity measure-
ments5. During the subsequent decades, the differences between
normal and OA SFs were characterized using multiple methods.
Generalizable relationships were described between the concen-
tration and average MW of HA, SF viscosity and elasticity, and the
effect of these parameters on biological processes relevant to joint
pathology6,7,8,9,10. In all of the above described relationships be-
tween HA MW and its biological activities, average values were
used for the MW of HA. Few prior studies have reported the MW
distribution of HA in SF and its change in patients with knee OA11. Intd. All rights reserved.
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the MW distribution of HA in SF is related to risk of knee OA
progression.
The concentration of HA in blood has likewise been reported to
change in patients with joint disease. Rheumatoid arthritis is
associated with a signiﬁcant and sustained increase in the plasma
concentration of HA, which increased signiﬁcantly with physical
activity and was sensitive to the total body load of inﬂamed
joints12,13. Plasma HA levels have also been suggested as an index of
the overall body burden of OA14. Several studies have reported that
elevation of the serum HA concentration is associated with the risk
of knee OA progression15,16,17. None of these prior studies have
clariﬁed the molecular basis for the reported relationship between
serum HA concentration and knee OA progression.
We therefore analyzed the MW distribution of HA in SF samples
available from the NIH-sponsored POP study (Prediction of OA
Progression), for which 3-year follow-up radiological data on knee
OA progression are available, including data on interval knee joint
replacement during the 3-year study period. We hypothesized that
the preponderance of low MW HA in SF would be associated with
the risk of OA progression.
Materials and methods
Patients, SF samples and radiographic progression status
As previously described18, patients enrolled in the POP study
had to have at least one knee with conﬁrmed symptomatic and
radiographic OA (the index knee), and to have consented to SF
withdrawal from both the index and contralateral knees. Baseline
SFs were available for 65 patient-knees from the 40 patients
involved in the NIH-sponsored POP study18; 40 of the 65 SF samples
analyzed were from the index knee used for inclusion in the orig-
inal POP study. The remaining 25 SF samples were from the
contralateral knees for 25 of the 40 patients. Samples were
included if there was sufﬁcient volume of SF, collected without
lavage, to analyze the MW distribution of HA. Therefore, the study
populations on whom we report here were enriched in patients
with effusion and clinical symptoms of inﬂammation at baseline.
Exclusion criteria included corticosteroid or hyaluronan injection
within the previous 3 months, history of avascular necrosis, rheu-
matoid or other inﬂammatory arthropathy, periarticular fracture,
Paget's disease, villonodular synovitis, joint infection, ochronosis,
neuropathic arthropathy, acromegaly, hemochromatosis, Wilson's
disease osteochondromatosis, arthroscopic knee surgerywithin the
previous 12 months, and bilateral knee replacement. Participants
were allowed to take all of their usual medications, including non-
steroidal anti-inﬂammatory drugs and dietary supplements such as
vitamins and glucosamine and/or chondroitin sulfate.
Posteroanterior ﬁxed-ﬂexion knee radiographs were obtained at
baseline and 3 years with the SynaFlexer lower limb positioning
frame (Synarc, San Francisco, California, USA) with a 10 caudal
X-ray beam angle. X-rays were scored with high inter-rater reli-
ability, as previously reported19 for individual radiographic features
of OA in the medial and lateral compartments for joint space nar-
rowing (JSN) and osteophytes (OST) on a scale of 0e3 using the
OARSI standardized atlas20. Total scores were 0e6 for JSN and 0e12
for OST as all four margins on the knee joint were scored for this
feature. Knees were scored as either positive (þ) or negative () for
JSN and OST separately, with an at least one-unit change deﬁned as
positive for progression. KellgreneLawrence radiographic scores
were assigned to each knee at baseline21. Knee symptoms were
ascertained by the National Health and Nutrition Examination Survey
(NHANES) I criterion22 of pain, aching, or stiffness on most days of
any 1 month in the last year; for subjects answering yes, symptomswere quantiﬁed as none, mild, moderate, or severe, yielding a total
score of 0e3 for each knee.
Analytic methods
SF HA concentration was determined using a commercially
available kit (Corgenix, Westminster, CO, USA). Prior to electropho-
retic analysis, SF samples were treatedwith 50 mg pronase per mg HA
to minimize interference due to contaminating proteins. The MW
distribution of HA in each SF sample was determined by agarose gel
electrophoresis (AGE)23, using MW standards for HA that were syn-
thesized to provide a narrow MW distribution, and hence discreet
bands on AGE. Three sets of standards were used to cover a broad
MW range: Super-mega ladder standards (SL, 2e8 million); Mega
ladder standards (ML, MW 1.5e6.1 million); and High ladder stan-
dards (HL, MW 0.51e1.5 million) (Hyalose, Inc. Oklahoma City, OK
USA). SF samples were diluted to a ﬁnal HA concentration of
0.3 mg/ml, so that 1.5 mg of HA (5 ml) was equally applied to all lanes.
Gels were stained in 0.005% Stains-All (3,30-dimethyl-9-methyl-
4,5,4050-dibenzothiacarbocyanine) in 50% ethanol for 16e24 h,
destained in 10% ethanol for 4e6 h, and scanned using a UMAX
Powerlook III scanner. The optical density of bound dyewas analyzed
using ImageMaster 1DElite, version4.10,AmershamBiosciences, and
plotted as the weight fraction (percent) of the total HA-bound dye
relative to the MW standards. For each SF sample, we calculated the
weight average molecular weight (Mw) of the HA, and the weight
fraction (weight-%) of the total HA-bound dye below an MW of 1
million. The arbitrary cutoff of 1 millionwas selected to focus on the
preponderance of HA molecules with below-normal MW. All ana-
lyses were performed with the investigator blinded to the progres-
sion status of the patient-knee associated with a given SF sample.
Statistical methods
Results are presented both for the set index knees, where in-
dependence between knees justiﬁes straightforward analyses, and
for the set of all knees, where the correlation between index and
contralateral knees in the same patient must be addressed.
Logistic regression was used to model the relationship between
the MW distribution of HA and OA progression over a 3-year
period. Covariates included in the model were BMI, age, gender,
baseline pain and radiographic grade. Generalized estimating
equations (GEE)24 were used to adjust for the correlation between
same-patient knees in the all-knee sample. In order to study the
association between baseline HA parameters and baseline pain,
Pearson's correlations were used and Fisher's Z-tests of signiﬁcance
were performed.
Descriptive statistics were used to compare the population in
whom HA MW distribution was analyzed to the rest of the POP
population (i.e., those knees from the POP population for which
sufﬁcient SF sample was not available for HA analysis). This was
done for both the index knee sample analyzed (40 knees vs 119
knees) and the full sample of study knees analyzed for HA (65 knees
vs 253 knees). Descriptive comparison of these cohorts was done
using Student's t-test (with clustered errors for the all-knee
sample).
Results
Patient population
The 65-knee sample and the 40 index-knee-only sample
analyzed in this study were generally typical of OA study pop-
ulations on most of the available characteristics. Although the SFs
analyzed for HA came from knees yielding somewhat more SF than
Fig. 1. Illustration of a representative result of hyaluronan (HA) electrophoresed on an
agarose gel to analyze the MW distribution of HA. Patients #38 and #39 were chosen
as examples because both had SF available for both the RK and LK. Patient #38 had K-L
grade 2 for both knees at baseline and TKA outcome for both knees. Patient #39 had K-
L grade 3 in both knees at baseline and OSTþ/JSN outcome for both knees. Patient
samples are in lanes 1 (#39 LK), 3 (#39, RK), 4 (#38, LK) and 6 (#38, RK). Lanes 7, 9 and
10 represent three sets of HA standards to cover a broad MW range: lane 7 Mega
ladder (ML) standards are 1.5, 3.1, 4.4 and 6.1 million MW; lane 9 High ladder (HL)
standards are 0.51, 0.67, 0.94, 1.14 and 1.5 million MW; and lane 10 Super-mega ladder
(SL) standards are 2, 4, 6 and 8 million MW.
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total POP population, with the exception of slightly greater mean
BMI at baseline in the 40-knee sample and slightly greater mean
knee pain at baseline in the 65-knee sample (Table I).
HA analysis
Figure 1 illustrates the MW distribution of HA on agarose gels
from two representative SF samples. Patients #38 and #39 were
chosen as examples because both had SF available for both the right
knee (RK) and left knee (LK), and they covered an interesting range
of baseline KellgreneLawrence (K-L) grades and 3-year outcomes;
patient #38 had bilateral knee K-L grade 2 at baseline and total
knee arthroplasty (TKA) outcomes for both knees; patient #39 had
bilateral knee K-L grade 3 at baseline and progression of osteo-
phytes (OSTþ/JSN) for both knees. The size distribution of HA was
determined by comparison with MW standards. Unlike the stan-
dards, SF HA did not run as discrete MW bands. This is because
naturally occurring HA is very polydisperse with respect to MW
compared to the HA standards, which are synthesized using care-
fully timed enzymatic reactions that enable production of a very
narrow MW distribution and hence sharp electrophoretic bands.
Visible differences in the MW distribution of HA are apparent be-
tween the patient-knees that progressed toTKA and those that only
progressed with respect to OST but not JSN (OSTþ/JSN); namely,
the SF of the knees of patient #38 (that progressed to TKA) had a
larger proportion of lower MW HA compared with SF from the
knees of patient #39. It is also interesting to note that the two knees
of each patient had a similar MWdistribution, and likewise, had the
same 3-year outcome.
Figure 2 plots the optical absorption of the HA-bound dye as a
function of MW, from laser scans of the agarose gel in Fig. 1, for
Patient 38, LK (TKA outcome) and patient 39, LK (OSTþ/JSN
outcome). The dye absorption value is expressed as the weight
fraction e i.e., the percent of the total amount of HA-bound dye in
the gel, at each MW interval. These plots are used to calculate the
samples' average MW (Mw), and the weight % of HA below 1
million, as illustrated by the dotted line at the MW corresponding
to 1 million. The latter is used as an index of the preponderance of
lower MW species in the SF sample. These plots highlight the dif-
ference in MW distribution between the two samples better than
the agarose gels themselves, and enable quantiﬁcation of between-
patient differences. In these examples, patient #38 has a weight %
below 1 million of 26% and 28% for the left and RK samples
respectively, while patient #39 has a weight % below 1 million of
14% and 11% for left and RK samples respectively.Table I
Demographic comparison of the patient-knee samples at baseline
Index knee
Non-HA index cohort HA index cohor
Patient-knees (n) 119 40
Mean Age (SD) 63.3 (11.5) 64.8 (12.7)
Sex (% Female) 77 68
Baseline Pain (0e3 scale) (SD) 1.7 (0.68) 1.8 (0.59)
BMI 30.5 (6.5) 33.2 (7.0)
KL grade distribution
0 3% 0%
1 24% 15%
2 14% 10%
3 53% 68%
4 6% 7%
* Indicates statistically signiﬁcant difference, P < 0.05.
y Comparison between 40 index knees and the rest of the index knees in the HA POP
z Comparison between 65 knees in HA cohort to the rest of the POP study populationKnee OA progression over the 3-year study period
Table II reports the means and SDs for each HA MW distribution
parameter for the patient subgroups by OA progression status.
Overall, approximately 12% (eight patient-knees) underwent TKAAll knees
t P-valuey Non-HA cohort HA cohort P-valuez
e 253 65 e
0.53 63.3 (11.7) 65.3 (12.0) 0.41
0.29 77 65 0.21
0.16 1.4 (0.75) 1.8 (0.65) 0.01*
0.03* 30.7 (6.5) 33.0 (7.3) 0.12
0.08 2% 2% 0.78
0.18 24% 12% 0.16
0.46 22% 11% 0.22
0.1 41% 57% 0.03*
0.73 7% 19% 0.07
population.
. Clustered errors used to account for within-patient correlations.
Fig. 2. Laser scan of selected lanes from the agarose gel in Fig. 1 for SF from patient #
38, LK, TKA outcome (top panel); and patient # 39, LK OSTþ/JSN outcome (bottom
panel). The area under the curve to the left of the vertical 1 million MW line represents
the weight %, preponderance of lower MW species in a sample. . In these examples,
patient #38 has a weight % below 1 million of 26% for the LK sample, while patient #39
has a weight % below 1 million of 14% for LK sample.
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11% experienced radiological progression with respect to both OST
and JSN, 37% experienced only OST progression and 40% experi-
enced no detectable radiologic deterioration. A similar distribution
was observed for the index-knee-only cohort (8%, 10%, 30%, and
52%, respectively). Notably, no patients fell into the JSNþ/OSTTable II
Mean (SD) values for the HA MW distribution parameters according to OA pro-
gression status, for the index knee sample (N ¼ 40), and the sample of all available
knees (N ¼ 65)
OA progression categories N (%) HA-weight
average MW
HA-weight
percent <1 mil
Index-knee only (N ¼ 40)
Non-progression (JSN/OST) 21 (53) 3.9 (0.55) 11.9 (5.09)
OST progression only (JSN/OSTþ) 12 (30) 3.86 (0.62) 13.42 (5.78)
Progression for both OST and
joint space width (JSNþ/OSTþ)
4 (10) 3.17 (0.59) 21.5 (8.19)
TKA patients 3 (8) 3.4 (0.53) 19 (4.36)
All available knees (N ¼ 65)
Non-progression (JSN/OST) 26 (40) 3.92 (0.56) 11.5 (5.22)
OST Progression only (JSN/OSTþ) 24 (37) 3.75 (0.87) 14.58 (5.76)
Progression for both OST and
joint space width (JSNþ/OSTþ)
7 (11) 3.66 (0.95) 17 (9.5)
TKA patients 8 (12) 3.51 (0.5) 16.75 (7.07)group, indicating that all patients who experienced progressive JSN
also experienced progressive OST, but the converse was not true.
Association between HA MW distribution and the risk of OA
progression
Table III provides the results of logistic regression analyses
performed to evaluate the relationship between the MW distribu-
tion of SF HA and the risk of knee OA progression, reported as odds
ratios (OR) and 95% conﬁdence intervals. For Mw, the odds of TKA
or JSN progression decreased (OR less than 1) as Mw increased. For
the weight-percent of HA below 1 million, the odds of TKA or JSN
progression increased (OR greater than 1) as the percent of the HA
below an MW of 1 million increased. The relationship between the
MW distribution of HA and the risk of OA progression was most
apparent for analyses that only included the index knees (N ¼ 40).
The weight-percent of HA below an MW of 1 million was the MW
distribution parameter that most consistently predicted the odds of
knee OA progression.
A strong association between the MWdistribution of HA and OA
progressionwas evident using logistic regression on the index knee
sample. Mw was signiﬁcantly associated with the odds of JSN
(OR ¼ 0.069, 95% CI (0.048e0.999) and TKA or JSN (OR ¼ 0.107, 95%
CI 0.015e0.757), in the model without covariates. Importantly, the
weight-percent of HA below 1 million remained signiﬁcantly
associated with the odds of progression when the full set of cova-
riates was included in the model. After adjusting for age, gender,
BMI, baseline X-ray grade and baseline pain, each 1 percentage
point increase in the weight-percent of HA below 1 million was
signiﬁcantly associated with the odds of JSN (OR ¼ 1.45, CI
1.02e2.07), TKA or JSN (OR ¼ 1.24, CI 1.01e1.53)) and the odds of
any progression (OR¼ 1.16, CI 1.01e1.32). This analysis predicts that
an increase of 5 percentage points in the weight-percent of HA
below 1 million would correspond to an approximately 6-fold in-
crease (¼1.455) in the odds of progressive JSN in the index knee
within the range of values reported here. These analyses also
demonstrate the utility of objective radiologic measures, compared
to complex measures such as the decision to undergo TKA, which is
impacted by multiple social and psychological factors.
For the full 65-knee cohort, Mw was not signiﬁcantly associated
with the odds of OA progression. However, the weight-percent of
HA below 1 million was signiﬁcantly associated with the odds of
TKA or JSN (OR ¼ 1.12, 95% CI 1.01e1.24), and with the odds of any
progression (OR ¼ 1.12, 95% CI 1.04e1.21) when using the model
that did not include any covariates, but not in the model that
included all covariates.
Association between baseline pain and HA MW distribution
All of the MW distribution parameters signiﬁcantly correlated
with baseline pain in this patient population (Table IV). This was
true for both the full 65 patient-knee sample, as well as for the
index-knee only sample. Mw negatively correlated to pain, indi-
cating that pain increased as Mw decreased. The percent of HA
below 1 million positively correlated to pain, indicating that as the
proportion of low MW species increased, pain increased.
Discussion
This study was motivated by two distinct lines of prior research:
(1) studies reporting that the HA in SF from patients with OA of the
knee has, on average, a lower concentration and MW compared to
SF from normal knees6,25; and (2) studies reporting an association
between the concentration of HA in serum and the risk of OA
progression15e17. Our analyses speciﬁcally address previously
Table III
Association between HA MW distribution parameters and the risk of OA progression
Index Knees (40)
TKA (N ¼ 3) þ/þ (N ¼ 4) TKA or þ/þ (N ¼ 7) Any progression (TKA, þ/þ, þ/) (N ¼ 19)
Weight Average MW Mean (OR and 95% Conﬁdence Intervals)
No adjustment 0.285 (0.031, 2.6) 0.069 (0.048, 0.999) 0.107 (0.0151, 0.757) 0.472 (0.154, 1.45)
Adjusted for BMI, Age, Gender, Pain, XR grade NA 0.002 (0, 1.45) 0.104 (0.0099, 1.09) 0.412 (0.109, 1.56)
Weight Fraction <1mil (OR and 95% Conﬁdence Intervals)
No adjustment 1.11 (0.933, 1.33) 1.27 (1.02, 1.57) 1.25 (1.05, 1.48) 1.12 (0.998, 1.27)
Adjusted for BMI, Age, Gender, Pain, XR grade 1.24 (0.642, 2.41) 1.45 (1.02, 2.07) 1.24 (1.01, 1.53) 1.16 (1.01, 1.33)
All Knees (65)
TKA (8) þ/þ (7) TKA or þ/þ (15) Any progression (TKA, þ/þ, þ/) (39)
Weight Average MW Mean (OR and 95% Conﬁdence Intervals)
No adjustment 0.502 (0.183, 1.38) 0.676 (0.137, 3.35) 0.416 (0.116, 1.5) 0.573 (0.226, 1.46)
Adjusted for BMI, Age, Gender, Pain, XR grade 0.716 (0.175, 2.93) 0.959 (0.165, 5.59) 0.833 (0.23, 3.01) 0.776 (0.254, 2.38)
Weight Fraction <1mil (OR and 95% Conﬁdence Intervals)
No adjustment 1.08 (0.966, 1.2) 1.1 (0.951, 1.28) 1.12 (1.01, 1.24) 1.12 (1.04, 1.21)
Adjusted for BMI, Age, Gender, Pain, XR grade 1.01 (0.89, 1.16) 1.07 (0.889, 1.28) 1.05 (0.931, 1.18) 1.1 (0.981, 1.23)
Logistic regression was used to analyze the association (OR, and 95%CI) between the baseline MW distribution parameters of HA in synovial ﬂuid, and the risk of radiographic
progression or TKA over the 3-year study period. For the all-knee analysis, GEEwere used to account for within-patient correlations. For Mw, the OR is expressed per 1million-
unit increase in MW. For the weight-percent below 1 million, the OR is expressed per 1 percent increase. þ/þ ¼ joint space narrowing and OST progression; þ/ ¼ OST
progression only; signiﬁcant values are in bold.
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and the MWof HA in SF, namely, the importance of measuring MW
distribution and the preponderance of lower MW HA. These ana-
lyses are intended to contribute to understanding the physiologic
and pathologic mechanisms that underlie the relationship between
HA and OA.
We report that a shift in the MW distribution of SF HA toward
lower values is associated with an increased risk for rapid OA
progression. Because HA can be cleaved by reactive oxygen species
generated during inﬂammation26,27, this ﬁnding is consistent with
the previously hypothesized relationship between inﬂammation
and rapid OA progression28,29. It is also consistent with data
reporting that high MW HA down-regulates inﬂammatory cell ac-
tivity8,10, and that HA fragments stimulate innate immune system
activity30,31. Our analyses therefore support the potential relevance
of evaluating the MW distribution of HA in SF as a means for
differentiating inﬂammatory and rapidly progressing OA pheno-
types from patients having a less progressive disease phenotype32.
These results also highlight the potential relevance of inﬂammation
as a therapeutic target for disease-modifying interventions.
Although not practical for clinical use as a diagnostic tool, AGE of SF
reveals the utility of measuring the MW distribution of HA, and the
limitations imposed when only average MW values are considered.
We also found that baseline pain was negatively correlated with
the MW of SF HA. This is consistent with prior reports demon-
strating an inverse relationship between pain, the rheological
properties of SF, and the average MW of SF HA33e36. Broadly
speaking, all these studies report that a decrease in SF viscoelas-
ticity, and/or the MW and concentration of HA, is associated with
increased pain. Our analyses conﬁrm this relationship in human
subjects, and additionally show that the preponderance of lowMWTable IV
Association between MW distribution parameters and baseline pain
MW distribution parameters Correlation to baseline pain* P-value
Index-knee only (n ¼ 40)
Weight Average Mw 0.35 0.03
Weight Percent < 1 mil 0.41 0.009
All available knees (n ¼ 65)
Weight Average Mw 0.363 0.003
Weight Percent < 1 mil 0.392 0.001
* Pearson correlation.HA is signiﬁcantly correlated to knee pain. As would be predicted,
pain increased as Mw decreased, while pain increased as the
weight % of HA below 1 million increased. This relationship be-
tween HA and pain is consistent with an association between low
MW HA and inﬂammation.
We performed separate analyses of the 40 index knees, and the
full 65-knee cohort from which SF was available. The index knees
presumably represent a more uniform and representative sample
because theywere used as the basis for inclusion in the original POP
study. In addition, the index knees are all from different patients
and are therefore independent of each other. We believe that our
observing similar results in both the full sample and the index
knee-only sample adds strength to our conclusions, and demon-
strates the robustness of the analysis.
There are a number of important caveats to bear in mind when
interpreting these results. Comparedwith the full POP cohort, the 65
knee samples from which SF was available for this study represent
knees that yielded a greater volume of SF at baseline, and which did
not require lavage to obtain a SF sample. Radiologic severity of dis-
ease was also somewhat more advanced in the sample we analyzed.
This may limit the generalizability of our conclusions to other OA
populations. A second important limitation of our analysis is that the
statistically signiﬁcant relationships we report should be interpreted
as descriptive rather than conclusive, because they do not take
multiplicity into account. Our results need to be conﬁrmed by a
prospective study that is appropriately powered for the multiple
associations being analyzed. Strengths of our analysis include the
blinding of all personnel performing laboratory measurements to
progression status, the scientiﬁc plausibility of the relationships
described, and the consistency of our ﬁndings with conclusions
drawn in other studies of inﬂammatory arthritic conditions37.
In conclusion, our data suggest that baseline OA pain, and the
risk of knee OA progression, are associated with the MW distribu-
tion of SF hyaluronan. The use of MW distribution parameters for
HA, rather than simple MW averages, provides an important tool
for probing the molecular basis of the relationship between HA and
OA, and potentially between HA and inﬂammation.
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